NEKTAR THERAPEUTICS WKN: 165417 ISIN: US6402681083 Kürzel: NKTR Forum: Aktien Thema: Hauptdiskussion
0,766 EUR
+0,10 %+0,001
11. Mar, 07:12:46 Uhr,
Quotrix Düsseldorf
Kommentare 257

Summer.76,
23.05.2022 17:07 Uhr
0
https://www.marketscreener.com/quote/stock/NEKTAR-THERAPEUTICS-45013433/news/NEKTAR-THERAPEUTICS-Other-Events-form-8-K-40517508/

Summer.76,
22.04.2022 20:21 Uhr
0
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
https://www.wfmz.com/news/pr_newswire/pr_newswire_stocks/nektar-therapeutics-to-host-webcast-conference-call-for-analysts-investors-to-outline-new-strategic-plan/article_c38773bc-e0e5-56f2-9766-2b07544203a8.html
....will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline. ...

Rentnergang,
18.04.2022 17:38 Uhr
0
🤔

Summer.76,
14.04.2022 23:18 Uhr
0
https://whtc.com/2022/04/14/nektar-bristol-myers-end-clinical-trial-program-for-cancer-drug-combo/
Nektar, Bristol Myers end clinical trial program for cancer drug combo
C
CB2020,
14.03.2022 17:35 Uhr
0
Sieht so aus

Fischi89,
14.03.2022 17:08 Uhr
0
Dann war das wohl eine fehlivest 🤦🏻♂️

Lirumlarum1,
14.03.2022 14:12 Uhr
0
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
https://www.businesswire.com/news/home/20220313005021/en/Bristol-Myers-Squibb-and-Nektar-Announce-Update-on-Phase-3-PIVOT-IO-001-Trial-Evaluating-Bempegaldesleukin-BEMPEG-in-Combination-with-Opdivo-nivolumab-in-Previously-Untreated-Unresectable-or-Metastatic-Melanoma

Lirumlarum1,
14.03.2022 14:07 Uhr
0
Nektar tumbles after melanoma combo therapy trial fails
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-nektar-melanoma-combo-therapy-trial-fails-meet-main-goals-2022-03-14/

Summer.76,
28.02.2022 22:19 Uhr
0
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-301491992.html

Summer.76,
15.12.2021 16:24 Uhr
0
https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-358-ly3471851-in-patients-with-atopic-dermatitis-301445396.html
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis

Summer.76,
04.11.2021 21:18 Uhr
0
Nektar Therapeutics Reports Third Quarter 2021 Financial Results
https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-third-quarter-2021-financial-results-301417106.html

Fischi89,
27.09.2021 16:51 Uhr
0
Gibt es News oder was ist hier los 😍

Summer.76,
21.09.2021 15:12 Uhr
0
https://www.prnewswire.com/news-releases/nektar-announces-new-clinical-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer-inc-to-combine-nktr-255-a-novel-interleukin-15-agonist-with-avelumab-in-the-javelin-bladder-medley-study-301380966.html
Nektar Therapeutics announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-15) receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study.
...

Summer.76,
05.08.2021 22:34 Uhr
0
Nektar Therapeutics Reports Second Quarter 2021 Financial Results
https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-second-quarter-2021-financial-results-301349775.html

Summer.76,
08.07.2021 17:49 Uhr
0
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
https://clinicaltrials.gov/ct2/show/NCT04955262
Recruitment Status : Withdrawn (Did not initiate due to business reasons. IND is inactive.)

Fischi89,
28.06.2021 8:12 Uhr
0
Gibt es News? Oder warum 5% hoch
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | EUTELSAT Hauptdiskussion | +2,01 % | |
2 | Trading- und Aktien-Chat | ||
3 | für alle, die es ehrlich meinen beim Traden. | ||
4 | NVIDIA Hauptdiskussion | +0,71 % | |
5 | TESLA MOTORS Hauptdiskussion | -9,94 % | |
6 | ATOS Hauptdiskussion | ±0,00 % | |
7 | SHOP APOTHEKE EUROPE INH. Hauptdiskussion | +1,31 % | |
8 | Nio für normale Kommunikation | +7,20 % | |
9 | DAX Hauptdiskussion | -2,71 % | |
10 | Aktien und Saunaclub alla Luci | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | EUTELSAT Hauptdiskussion | +2,01 % | |
2 | NVIDIA Hauptdiskussion | +0,71 % | |
3 | TESLA MOTORS Hauptdiskussion | -9,94 % | |
4 | ATOS Hauptdiskussion | ±0,00 % | |
5 | SHOP APOTHEKE EUROPE INH. Hauptdiskussion | +1,31 % | |
6 | Nio für normale Kommunikation | +7,20 % | |
7 | BIGBEAR by Honspeda | +0,53 % | |
8 | HELLOFRESH SE INH O.N. Hauptdiskussion | +0,76 % | |
9 | Drone Volt neue ISIN | ±0,00 % | |
10 | XIAOMI CORP. CL.B Hauptdiskussion | +2,93 % | Alle Diskussionen |